Michelle Gilson
Stock Analyst at Morgan Stanley
(1.10)
# 3,801
Out of 5,031 analysts
31
Total ratings
32.14%
Success rate
-6.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $5.78 | +246.02% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $78.69 | -61.88% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $8.69 | +95.63% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $210.50 | -6.89% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $27.32 | +64.71% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $33.53 | +126.66% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $53.29 | +70.76% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $5.78
Upside: +246.02%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $78.69
Upside: -61.88%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $8.69
Upside: +95.63%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $210.50
Upside: -6.89%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $27.32
Upside: +64.71%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $33.53
Upside: +126.66%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $53.29
Upside: +70.76%